Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC

Summary by Benzinga
Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC. Foresee will receive a 10 million USD upfront payment, potential milestones of up to 584.5 million USD, single-digit royalties and retains a 19% equity in Primevera, ensuring participation in future value creation. TAIPEI, Jan. 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced, following approv…

1 Articles

BenzingaBenzinga
Center

Foresee Pharmaceuticals announces Global Licensing Agreement for MMP-12 Inhibitors with Primevera Therapeutics LLC

Foresee licenses exclusive global rights related to its MMP-12 inhibitor programs to Primevera Therapeutics, LLC. Foresee will receive a 10 million USD upfront payment, potential milestones of up to 584.5 million USD, single-digit royalties and retains a 19% equity in Primevera, ensuring participation in future value creation. TAIPEI, Jan. 8, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced, following approv…

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Thursday, January 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Taipei icon

Taipei

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal